Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT (CROSBI ID 326041)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Devillier, Raynier ; Galimard, Jacques-Emmanuel ; Labopin, Myriam ; Blaise, Didier ; Raiola, Anna Maria ; Pavlu, Jiri ; Castagna, Luca ; Socié, Gerard ; Chalandon, Yves ; Martino, Massimo et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT // Bone marrow transplantation (Basingstoke), 57 (2022), 1421-1427. doi: 10.1038/s41409-022-01674-x

Podaci o odgovornosti

Devillier, Raynier ; Galimard, Jacques-Emmanuel ; Labopin, Myriam ; Blaise, Didier ; Raiola, Anna Maria ; Pavlu, Jiri ; Castagna, Luca ; Socié, Gerard ; Chalandon, Yves ; Martino, Massimo ; Stölzel, Friedrich ; Bug, Gesine ; Bruno, Benedetto ; Vrhovac, Radovan ; Charbonnier, Amandine ; Olivieri, Attilio ; Bay, Jacques-Olivier ; Arroyo, Herrera ; Yakoub-Agha, Ibrahim ; Avenoso, Daniele ; Neubauer, Andreas ; Nguyen, Stéphanie ; Forcade, Edouard ; Brissot, Eolia ; Savani, Bipin ; Nagler, Arnon ; Mohty, Mohamad

engleski

Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT

The optimal conditioning regimen prior haploidentical stem cell transplantation (Haplo-SCT) with post transplantation cyclophosphamide (PT-Cy) for acute myeloid leukemia (AML) remains unknown. A non-myeloablative conditioning (NMAC) regimen (cyclophosphamide + fludarabine + TBI 2 Gy [CyFluTBI]) is a safe approach, but relapse incidence remains high in this setting. Alternatively, a reduced intensity conditioning (RIC) regimen combining thiotepa and reduced-dose busulfan with fludarabine (TBF) may decrease AML relapse. However, an excess of toxicity may counterbalance this potential benefit. We retrospectively compared CyFluTBI vs. TBF in CR AML patients who underwent Haplo-SCT with PT-Cy, in two different populations based on age. We analyzed 490 patients. In patients aged <60 years (n = 203), we observed a higher RI (HR = 3.59, 95% CI = 1.75–7.37, p < 0.01), lower LFS (HR = 1.98, 95% CI = 1.22–3.22, p < 0.01) and lower OS (HR = 1.73, 95% CI = 1.04– 2.88, p = 0.04) in the CyFluTBI group, without significant difference in NRM. In older patients (n = 287), we observed that conditioning regimen did not significantly influence LFS (HR = 0.90, 95% CI = 0.56–1.44, p = 0.65), OS (HR = 0.81, 95% CI = 0.49–1.32, p = 0.39) and RI (HR = 1.78, 95% CI = 0.90–3.50, p = 0.10), but showed that CyFluTBI was associated with a significantly lower risk of NRM (HR = 0.48, 95% CI = 0.25–0.92, p = 0.03). Thus, younger patients seem to benefit from conditioning intensification from CyFluTBI to TBF regimens prior PT-Cy Haplo-SCT for CR AML, while older ones do not.

reduced intensity ; non-myeloablative ; conditioning ; acute myeloid leukemia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

57

2022.

1421-1427

objavljeno

0268-3369

1476-5365

10.1038/s41409-022-01674-x

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost